Nesiritide
- Generic Name
- Nesiritide
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 124584-08-3
- Unique Ingredient Identifier
- P7WI8UL647
- Background
Nesiritide is a medication used to treat acutely decompensated congestive heart failure with dyspnea at rest or with minimal exertion (such as talk, eating or bathing). Nesiritide is a 32 amino acid recombinant human B-type natriuretic peptide.
- Indication
适用于急性代偿性心力衰竭、慢性失代偿性心力衰竭、心肌梗死、心脏导管手术等。由于静脉使用起效快，更适用于急性心力衰竭。
- Associated Conditions
- Acute Decompensated Heart Failure (ADHF)
- Associated Therapies
- -
Nesiritide and Renal Function After the Total Artificial Heart
- Conditions
- Interventions
- First Posted Date
- 2013-04-22
- Last Posted Date
- 2016-02-08
- Lead Sponsor
- Virginia Commonwealth University
- Target Recruit Count
- 2
- Registration Number
- NCT01836809
- Locations
- 🇺🇸
Virginia Commonwealth University Medical Center, Richmond, Virginia, United States
Recombinant BNP on Heart and Renal Function in Acute Heart Failure
- Conditions
- Interventions
- First Posted Date
- 2012-06-21
- Last Posted Date
- 2012-08-07
- Lead Sponsor
- Shanghai Chest Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT01625403
- Locations
- 🇨🇳
Shanghai Chest Hospital, Shanghai, Shanghai, China
Tadalafil and Nesiritide as Therapy in Pre-clinical Heart Failure
- Conditions
- Interventions
- First Posted Date
- 2012-03-06
- Last Posted Date
- 2018-03-22
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 43
- Registration Number
- NCT01544998
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
Does Nesiritide Provide Renal Protection
- First Posted Date
- 2011-09-27
- Last Posted Date
- 2014-06-06
- Lead Sponsor
- University of Florida
- Target Recruit Count
- 37
- Registration Number
- NCT01440881
- Locations
- 🇺🇸
University of Florida, Gainesville, Florida, United States
Brain Natriuretic Peptide Effects on Appetite Regulating Hormones and Endothelial Derived Peptides
- First Posted Date
- 2011-06-17
- Last Posted Date
- 2017-04-06
- Lead Sponsor
- Medical University of Vienna
- Target Recruit Count
- 10
- Registration Number
- NCT01375153
- Locations
- 🇦🇹
AKH, Medical University of Vienna, Vienna, Austria
🇦🇹Medical University of Vienna, Vienna, Austria
Renal Optimization Strategies Evaluation in Acute Heart Failure and Reliable Evaluation of Dyspnea in the Heart Failure Network (ROSE) Study
- Conditions
- Interventions
- First Posted Date
- 2010-05-28
- Last Posted Date
- 2014-08-21
- Lead Sponsor
- Duke University
- Target Recruit Count
- 360
- Registration Number
- NCT01132846
- Locations
- 🇺🇸
University of Utah Health Sciences Center, Murry, Utah, United States
🇺🇸Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸University of Vermont- Fletcher Allen Health Care, Burlington, Vermont, United States
Low Dose Intravenous (IV) Infusion of BNP in the Presence and Absence of Acute Type V Phosphodiesterase (PDE V) in Improving Renal Function in Hospitalized Chronic Heart Failure (CHF) Patients With Renal Dysfunction
- First Posted Date
- 2009-09-07
- Last Posted Date
- 2020-01-18
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 60
- Registration Number
- NCT00972569
Assessment of Biomarkers and Cardiorenal Syndrome in Acute Decompensated Heart Failure With Vasodilator Therapy
- Conditions
- Interventions
- First Posted Date
- 2009-02-12
- Last Posted Date
- 2013-08-30
- Lead Sponsor
- Western University of Health Sciences
- Target Recruit Count
- 89
- Registration Number
- NCT00842023
- Locations
- 🇺🇸
Centinela Hospital Medical Center, Inglewood, California, United States
An Open-label, One-arm, Study to Evaluate the Hemodynamic Changes and Safety of Nesiritide for Acute Decompensated Heart Failure
- First Posted Date
- 2008-12-22
- Last Posted Date
- 2014-02-28
- Lead Sponsor
- Xian-Janssen Pharmaceutical Ltd.
- Target Recruit Count
- 41
- Registration Number
- NCT00813202
Nesiritide - Dilated Cardiomyopathy
- Conditions
- Interventions
- First Posted Date
- 2008-07-03
- Last Posted Date
- 2008-07-03
- Lead Sponsor
- University of California, Los Angeles
- Target Recruit Count
- 20
- Registration Number
- NCT00709163
- Locations
- 🇺🇸
Mattel Children's Hospital at UCLA, Los Angeles, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.